Rituximab for the treatment of multiple sclerosis: a review
Clara Grazia Chisari(University of Catania), Francesco Patti(University of Catania)
Cited by 204
Related Papers
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
|Journal of Neurology|2022|187
Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis
|JAMA Neurology|2021|183
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study
|Brain|2022|158
Effects of a short outpatientrehabilitation treatment on disability of multiple sclerosispatients
|Journal of Neurology|2003|99
Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar
|Multiple Sclerosis and Related Disorders|2022|60